Human Volunteers Clinical Trial
Official title:
A Phase I, Open-Label, Fixed Sequence Study To Estimate The Steady-State Effect Of Ketoconazole On The Single-Dose Pharmacokinetics Of PF-04937319 In Healthy Adult Subjects
Verified date | November 2011 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This study will evaluate the potential for a drug-drug interaction of PF-04937319 with ketoconazole, a potent inhibitor of the drug metabolizing enzyme CYP3A.
Status | Completed |
Enrollment | 10 |
Est. completion date | October 2011 |
Est. primary completion date | October 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG or clinical laboratory tests. - Body Mass Index (BMI) of 17.5 to 29.9 kg/m2; and a total body weight >=50 kg (110 lbs). - Subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 28-days after the last dose of treatment. Exclusion Criteria: - Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. - Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of non-hormonal contraception - Consumption of grapefruit-containing products within 7 days prior to the first dose of study medication and while in the study protocol from at least 14 days prior to the first dose of study medication and for at least 28 days after the last dose of study medication |
Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
United States | Pfizer Investigational Site | New Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cmax of PF-04937319 | Day 1 & Day 6 | No | |
Primary | Tmax of PF-04937319 | Day 1 & Day 6 | No | |
Primary | AUClast of PF-04937319 | Day 1 & Day 6 | No | |
Primary | (as data permits) AUCinf of PF-04937319 | Day 1 & Day 6 | No | |
Primary | (as data permits) t1/2 of PF-04937319 | Day 1 & Day 6 | No | |
Primary | Cmax of PF-04937319 M1 metabolite | Day 1 & Day 6 | No | |
Primary | Tmax of PF-04937319 M1 metabolite | Day 1 & Day 6 | No | |
Primary | AUClast of PF-04937319 M1 metabolite | Day 1 & Day 6 | No | |
Primary | (as data permits) AUCinf of PF-04937319 M1 metabolite | Day 1 & Day 6 | No | |
Primary | (as data permits) t1/2 of PF-04937319 M1 metabolite | Day 1 & Day 6 | No | |
Secondary | Urinary recovery of PF-04937319 M1 metabolite | Day 1 | No | |
Secondary | (as data permits) renal clearance (CLr) of PF-04937319 M1 metabolite | Day 1 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03093506 -
Effects of Micro-dose and Low-dose Recombinant Human Erythropoietin on Mitochondrial Function and Cognitive Performance
|
Early Phase 1 | |
Completed |
NCT00526968 -
The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function
|
Phase 1 | |
Completed |
NCT03277456 -
A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1
|
Early Phase 1 | |
Completed |
NCT02922933 -
A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT01452425 -
In Vivo Optical Spectroscopy Monitoring in a New Model of Muscular Compartment Syndrome
|
Phase 1 | |
Completed |
NCT01464385 -
Nutrition Beverage Tolerance Study
|
Phase 2 | |
Completed |
NCT02922946 -
Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat
|
Phase 1 | |
Completed |
NCT00254449 -
Effect of NGX-4010 on ENFD and Sensory Function
|
Phase 1 | |
Completed |
NCT01618877 -
A Randomized, Double-blind, Pharmacokinetics Study to Assess Safety, Tolerability of Levetiracetam 45 Minutes Intravenous Infusion During 4 Days of Bid Dosing in Chinese Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01618903 -
An Open-label, Bioequivalence Study to Evaluate LEV Administered as a 45-min Intravenous Infusion and Same Dosage LEV Oral Tablet in Chinese
|
Phase 1 | |
Completed |
NCT00752466 -
A Drug Interaction Study of the Pharmacokinetics of Topiramate and FLUNARIZINE When Given Together or Separately
|
Phase 1 | |
Completed |
NCT00166933 -
Minimal Erythema Dose of UV-B in Normal Population of Taiwan
|
N/A | |
Completed |
NCT05519514 -
Bio-Equivalence Study of Budesonide Prolonged-release Tablets 9 Mg In Healthy Human Adult Subjects
|
Phase 1 | |
Completed |
NCT01776437 -
Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers
|
Phase 1 | |
Completed |
NCT01437033 -
Breath Test for Chemicals (Volatile Organic Compounds)
|
||
Completed |
NCT01445860 -
Drug-Drug Interaction Study Of Effect Of PF-03882845 On Simvastatin Pharmacokinetics
|
Phase 1 | |
Completed |
NCT00744809 -
TMC278-TiDP6-C152: A Study to Assess the Effects of TMC278 and Efavirenz (EFV) on the QT/QTc Interval (Heart Conduction and Heart Rhythm) in Healthy Volunteers.
|
Phase 1 | |
Unknown status |
NCT00743977 -
Bioequivalence of Phenazopyridine HCl in Healthy Volunteers
|
N/A |